Pain News and Research

Latest Pain News and Research

Banner Good Samaritan treats cancers and neurological disorders with the Novalis Tx radiosurgery platform

John J. Kresl, M.D., Ph.D., and colleagues at Banner Good Samaritan Medical Center are now treating a wide variety of cancers and neurological disorders with highly-accurate, non-invasive, image-guided radiosurgery using the Novalis Tx(TM) radiosurgery platform from Varian Medical Systems (NYSE: VAR) and BrainLAB.

4 Sep 2009

China Aoxing submits an NDA to the China SFDA for its Codeine Phosphate

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing"), a pharmaceutical company specializing in research, development, manufacturing and marketing of narcotic and pain-management products, today announced that it has submitted a new drug application (NDA) to the China State Food and Drug Administration (SFDA) for its Codeine Phosphate, a compound oral solution for the treatment of acute moderate to severe cough.

3 Sep 2009

China Sky One Medical submits application to perform clinical trials for two new generic drugs

China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company has finished the required research for two new generic drugs for eye treatment and submitted application to the State Food and Drug Administration (SFDA) in China to perform clinical trials.

3 Sep 2009

MPI Research appoints Executive Vice President of Sales and Marketing

MPI Research announced today that Thomas Laughlin will join the company as Executive Vice President of Sales and Marketing and will be a member of the company’s Corporate Management Team. Laughlin’s 30+ years of executive experience span several of the world’s largest and most successful healthcare products companies.

3 Sep 2009

Corporate restructuring announced by Akela Pharma to achieve several operational objectives

Akela Pharma, Inc., (TSX: AKL) and its wholly owned manufacturing subsidiary, PharmaForm, today announced a comprehensive corporate restructuring designed to achieve several operational objectives.

3 Sep 2009

Ethical Alternative Products launches the OmniFlex joint support formula

Ethical Alternative Products has launched OmniFlex, a unique joint support formula combining five highly researched ingredients shown specifically to positively impact joint structure and function in easy-to-swallow soft-gel capsules.

3 Sep 2009

Atlantic Health uses SuccessFactors Performance and Talent Management Suite

SuccessFactors, Inc., the global leader in on-demand performance and talent management solutions, announced today that Atlantic Health, which was recently named by FORTUNE as one of the "100 Best Companies To Work For," is using SuccessFactors Performance and Talent Management Suite to help improve overall business performance by aligning employee performance goals with overall company goals, and streamline its talent management processes.

3 Sep 2009

First swine-flu vaccine trials reveal strong immune response

Results from the first swine-flu vaccine trials taking place in Leicester reveal a strong immune response after just one dose.

3 Sep 2009

New Marketing Authorization Application for Rhucin submitted to the EMEA by Pharming

Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has submitted the Marketing Authorization Application (MAA) for Rhucin for the treatment of acute attacks of Hereditary Angioedema (HAE) to the European Medicines Agency (EMEA).

3 Sep 2009

CORD I phase III clinical trial results of XIAFLEX published

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that The New England Journal of Medicine (NEJM) has published in its September 3rd edition, the Company's pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum) a novel, first-in-class, biologic for the nonsurgical treatment of Dupuytren's contracture.

3 Sep 2009

New electronic medical device for treating leg pain

ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from peripheral neuropathy and Peripheral Artery Disease today announced that it has released a new way to deliver the impulses of the ReBuilder for pain.

3 Sep 2009

Clinical trial results of sumatriptan published in a journal

NovaDel Pharma Inc. announced that an article titled “Rapid Oral Transmucosal Absorption of Sumatriptan, and Pharmacodynamics in Acute Migraine” was published online on June 22, 2009 in the peer-reviewed journal Headache: The Journal of Head and Face Pain.

3 Sep 2009

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

A key compound resupplies bone marrow with fast-acting stem cells that can more quickly rekindle blood cell production, according to a study published online today in the journal Blood. While the study was in mice, in the study authors say it has the potential to increase survival among patients with life-threatening blood cell shortages.

3 Sep 2009

GDC-0449 inhibits the Hedgehog signaling pathway

The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage.

3 Sep 2009

Sepracor to be acquired by Dainippon Sumitomo Pharma for $2.6 billion

Dainippon Sumitomo Pharma Co., Ltd. (“DSP”, TSE: 4506) and Sepracor Inc. (“Sepracor”, Nasdaq: SEPR) today announced that they have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share, followed by a merger to acquire all remaining outstanding Sepracor shares at the same price paid in the tender offer.

3 Sep 2009

Research reveals that 21% of death claims are rejected by California's largest private insurers

More than one of every five requests for medical claims for insured patients, even when recommended by a patient's physician, are rejected by California's largest private insurers, amounting to very real death panels in practice daily in the nation's biggest state, according to data released today by the California Nurses Association/National Nurses Organizing Committee.

3 Sep 2009

Yale University awarded $36 million ARRA funds for over 100 research projects

Faculty at Yale University have been awarded over 100 research grants totaling $36 million since February 2009, when the federal stimulus package was signed into law. Known as the American Recovery and Revitalization Act of 2009 (ARRA), the law aims to reinvigorate the economy and lay the foundation for long-term economic recovery by increasing investments in infrastructure, education, the environment and scientific research.

3 Sep 2009

Bextra qui tam lawsuit leads to Pfizer's whopping $2.3 billion settlement

The decision by a Pfizer sales representative in Florida to file a whistleblower ("qui tam") lawsuit in 2003 kicked off the federal and state investigations that led to Pfizer's record-breaking $2.3 billion settlement today.

3 Sep 2009

Tort reform and changes to doctor payment could cut health costs

Limiting medical malpractice lawsuits and changing the doctor payment system are being debated as possible ways to make health care more cost-effective.

3 Sep 2009

New method for treating hand disorder discovered

Researchers in the Department of Orthopaedics at Stony Brook University Medical Center have developed an injectable form of the enzyme, collagenase, that significantly improves outcomes of Dupuytren's contracture (or disease), a debilitating disorder caused by progressive accumulation of collagen that deforms fingers and limits motion. Reported in September 3, 2009, issue of The New England Journal of Medicine, the study involved treatment of 308 patients with Duputren's disease in 16 sites nationwide. The results indicate that the injections are safe and effective.

3 Sep 2009